Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma

Pemetrexed‐cisplatin chemotherapy is the standard of care in the first‐line treatment of unresectable malignant pleural mesothelioma (MPM). Second‐line cytotoxic therapy is considered for a growing group of patients, but the optimal treatment has not been defined to date. Gemcitabine and vinorelbine have shown activity in the first‐line setting. The objective of this study was to evaluate the activity and toxicity of the gemcitabine‐vinorelbine combination in pemetrexed‐pretreated patients with MPM.

[1]  R. Stephens,et al.  A randomized phase III trial of active symptom control (ASC) with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma: First results of the Medical Research Council (MRC) / British Thoracic Society (BTS) MS01 trial , 2007 .

[2]  J. Sørensen,et al.  Pemetrexed as Second-Line Treatment in Malignant Pleural Mesothelioma after Platinum-Based First-Line Treatment , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  G. Giaccone,et al.  Biology and management of malignant pleural mesothelioma. , 2006, European journal of cancer.

[4]  M. van Glabbeke,et al.  Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Ceribelli,et al.  Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Shamash,et al.  P-397 Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage , 2005 .

[7]  C. Porta,et al.  Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. , 2005, Lung cancer.

[8]  K. Nackaerts,et al.  Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  V. Rusch Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Paccagnella,et al.  Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma , 2003, Cancer.

[12]  G. Scagliotti,et al.  Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Schreiber,et al.  A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. , 2003, Clinical lung cancer.

[14]  T. Chevalier,et al.  Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Giaccone,et al.  Phase II trial of ZD0473 as second-line therapy in mesothelioma. , 2002, European journal of cancer.

[16]  D. Fielding,et al.  A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma , 2002, British Journal of Cancer.

[17]  O. S. Nielsen,et al.  Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. , 2002, European journal of cancer.

[18]  R. V. van Klaveren,et al.  Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma , 2002, British Journal of Cancer.

[19]  J. V. van Meerbeeck,et al.  The role of gemcitabine in the treatment of malignant mesothelioma. , 2002, Seminars in oncology.

[20]  J. Shamash,et al.  Phase II study of vinorelbine in patients with malignant pleural mesothelioma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  N. Vogelzang Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma? , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Giaccone,et al.  A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. , 1999, Cancer.

[23]  G. Giaccone,et al.  A phase II study of gemcitabine in patients with malignant pleural mesothelioma , 1999 .

[24]  F Levi,et al.  The European mesothelioma epidemic , 1999, British Journal of Cancer.

[25]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[26]  V. Rusch A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. , 1995, Chest.

[27]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[28]  E. Gehan A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. , 1965, Biometrika.

[29]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[30]  J. Shamash,et al.  Efficacy and safety of first‐ or second‐line irinotecan, cisplatin, and mitomycin in mesothelioma , 2007, Cancer.

[31]  Mark R. Green,et al.  Carboplatin in malignant mesothelioma: A phase II study of the cancer and leukemia Group B , 2004, Cancer Chemotherapy and Pharmacology.

[32]  I. Smith,et al.  Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma , 2004, Cancer Chemotherapy and Pharmacology.

[33]  R Simon,et al.  Clinical trial designs for cytostatic agents: are new approaches needed? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Ducreux,et al.  A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  A. Musk,et al.  Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Giaccone,et al.  Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  P. Bye,et al.  Phase II trial of carboplatin in the management of malignant mesothelioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.